Skip to main content
Premium Trial:

Request an Annual Quote

Orion and VBI Sign Diagnostic-Development Deal for Viral Pathogens

NEW YORK, Feb. 7 (GenomeWeb News) - The Virginia Bioinformatics Institute at Virginia Tech and Orion Integrated Biosciences plan to co-develop new diagnostic methods for viral pathogens, the partners said today.


Under the agreement, VBI will integrate data on encephalic and hemorrhagic viruses from its PathPort project into Orion's integrated computational analysis system.


"The lack of diagnostic tools that can integrate and analyze molecular surveillance data is a major gap in disease prevention and the development of countermeasure responses," said Oswald Crasta, director of bioinformatics for VBI's cyberinfrastructure group.


Financial details of the deal  were not provided.


VBI 's PathPort platform includes pathogens with the potential use as biological weapons, according to the statement.


New York-based Orion Integrated Biosciences is a drug-discovery and viral disease detection shop, focusing on the development of antiviral agents and devices that can recognize lethal pathogens in medical and military settings.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.